# Sargramostim for Myeloid Dendritic Cell Deficiency

> **NCT03063242** · PHASE2 · TERMINATED · sponsor: **University of Florida** · enrollment: 4 (actual)

## Conditions studied

- Kidney Diseases
- Kidney Transplant

## Interventions

- **DRUG:** Sargramostim
- **BIOLOGICAL:** Blood samples

## Key facts

- **NCT ID:** NCT03063242
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-23
- **Primary completion:** 2018-09-17
- **Final completion:** 2018-09-17
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Insufficient resources necessary for completion.
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03063242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03063242, "Sargramostim for Myeloid Dendritic Cell Deficiency". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03063242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*